Emibetuzumab, previously known as LY2875358, represents a novel therapeutic method in oncology, specifically targeting the MET tyrosine kinase. This engineered antibody works by specifically binding to the MET https://dirstop.com/story28766488/emibetuzumab-a-deep-analysis-into-the-ly2875358-anti-hepatocyte-growth-factor-receptor-antibody